Vitamin A and D Supplementation in Allogeneic HCT

The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for allogeneic transplantation with matched related or matched unrelated donor.

Trial Details

NCT ID
NCT06508099
Phase
PHASE2
Sponsor
St. Petersburg State Pavlov Medical University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Vitamin A
  • Vitamin D3
Locations (sample)
  • Saint Petersburg, Russia|59.93863,30.31413

Key Eligibility Criteria

  • Diagnosis: acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloproliferative disease, chronic myeloid leuk…
  • Standard disease risk: less than 5% clonal blasts in the bone marrow and the absence of blast forms in the peripheral blood at the time of inclusio…
  • Related compatible donor 10/10 HLA-matched or unrelated compatible donor 9-10/10 HLA-matched
  • Age ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →